Skip to main content
Clinical Trials/NCT05874141
NCT05874141
Recruiting
Not Applicable

Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, Egypt

New Valley University1 site in 1 country288 target enrollmentNovember 15, 2023
ConditionsType 2 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
New Valley University
Enrollment
288
Locations
1
Primary Endpoint
Number of participants with Liver disease
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

Detailed Description

All-cause mortality rates have declined substantially in several high-income countries, including England. A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex. Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially. Many studies have primarily focused on identifying multimorbidity patterns in the general population. The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.

Registry
clinicaltrials.gov
Start Date
November 15, 2023
End Date
August 30, 2026
Last Updated
8 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Asmaa Nady Hussein

Lecturer of Internal Medicine and Clinical Hematology

New Valley University

Eligibility Criteria

Inclusion Criteria

  • Patients with type 2 diabetes.

Exclusion Criteria

  • Patients with type 1 diabetes.
  • Patients with secondary diabetes.

Outcomes

Primary Outcomes

Number of participants with Liver disease

Time Frame: At time of inclusion in the study

Number of participants with hypertension

Time Frame: At time of inclusion in the study

Number of participants with thyroid disorder

Time Frame: At time of inclusion in the study

Number of participants with Coronary heart disease

Time Frame: At time of inclusion in the study

Number of participants with Infections

Time Frame: At time of inclusion in the study

Number of participants with dyslipidemia

Time Frame: At time of inclusion in the study

Number of participants with Diabetic kidney disease

Time Frame: At time of inclusion in the study

Number of participants with Stroke

Time Frame: At time of inclusion in the study

Number of participants with Peripheral arterial disease

Time Frame: At time of inclusion in the study

Number of participants with Diabetic eye disease

Time Frame: At time of inclusion in the study

Number of participants with Peripheral neuropathy

Time Frame: At time of inclusion in the study

Number of participants with Cancer

Time Frame: At time of inclusion in the study

Secondary Outcomes

  • Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity(At time of inclusion in the study)
  • Correlate the presence of each co-morbidity with the extent of diabetes control(At time of inclusion in the study)

Study Sites (1)

Loading locations...

Similar Trials